Nuvalent
ongoing selection supported by favorable profiles phase dose levels may provide increased coverage of single and compound mutations in the exposure achieved predicted efficacy thresholds induced clearance of diverse alk resistance mutation alleles at steady state day clearance observed in patients with centrally confirmed alk or wat pea mutations of whom had received prior clearance of alk mutations detected in plasma key mutation or mutation seed mutation received i prior a a ase i predicted efficacy thresholds alk single mutation alk compound mutations alk naive alk single mutation as a i a a a at at fat ers sess aas sad aga bad hoy a a ass sea a bots ort i i a dose ere data for cohort are not shown due to immaturity based on tumor growth inhibition best response in in models bearing hip alk alk alk and alk respectively divided predicted human brain to plasma ratio targets for exceed corresponding periphery values data are shown for all treated patients with alk mutations detected on cycle day and with at least one follow up assessment one patient with only an alk mutant of unknown significance is not included on the graph brackets indicate pairs with evidence of allelic configuration central analysis refers to single or compound mutations alk mutant variant of unknown significance available data for patients enrolled as of central nervous system hours pharmacodynamics patient once daily standard deviation source lin | Nuvalent
Company
Deck date
January 2024
Slide
19 of 42
Other recent decks by Nuvalent
Investor Presentation
April 2024
Investor Presentation
February 2024
Investor Presentation
January 2024
Investor Presentation
November 2023
Search Thousands of Presentations by World Leading Companies

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases
© 2021-2024 Slidebook.io